Physician profile
Ann E Ranelle
NPI 1427030139
$1,062.20
in general payments reported to CMS, 2019-2025
18 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $61.86 · 2021: $255 · 2022: $51.29 · 2023: $94.43 · 2024: $141 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.39 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $187.08 | 2019-2025 | Cequa |
| Alcon Vision LLC | $148.79 | 2023-2025 | Rocklatan, Simbrinza, Rhopressa |
| Aerie Pharmaceuticals, INC. | $120.18 | 2021 | |
| Horizon Therapeutics Plc | $112.41 | 2021-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $100.52 | 2019 | |
| Biotissue Holdings INC. | $65.87 | 2025 | |
| Rxsight INC | $51.81 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Allergan, INC. | $41.97 | 2020-2022 | |
| Amgen INC. | $37.57 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $32.40 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $27.06 | 2019-2021 | |
| Sight Sciences, INC. | $22.82 | 2023 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $22.16 | 2021 | |
| Galderma Laboratories, L.P. | $21.06 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.62 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.68 | 2021 | |
| Glaukos Corporation | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ranelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.